182 related articles for article (PubMed ID: 18959062)
21. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
[TBL] [Abstract][Full Text] [Related]
22. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
Hollak CE; vom Dahl S; Aerts JM; Belmatoug N; Bembi B; Cohen Y; Collin-Histed T; Deegan P; van Dussen L; Giraldo P; Mengel E; Michelakakis H; Manuel J; Hrebicek M; Parini R; Reinke J; di Rocco M; Pocovi M; Sa Miranda MC; Tylki-Szymanska A; Zimran A; Cox TM
Blood Cells Mol Dis; 2010 Jan; 44(1):41-7. PubMed ID: 19804996
[TBL] [Abstract][Full Text] [Related]
23. [Gaucher disease type I diagnosed at 63 years old presenting with thrombocytopenia].
Kawahara S; Kato A; Oshimi K; Ida H
Rinsho Ketsueki; 2008 May; 49(5):335-9. PubMed ID: 18572811
[TBL] [Abstract][Full Text] [Related]
24. Increased red blood cell aggregation in patients with Gaucher disease is non-inflammatory.
Adar T; Ben-Ami R; Elstein D; Zimran P; Berliner S; Yedgar S; Barshtein G
Clin Hemorheol Microcirc; 2008; 40(2):113-8. PubMed ID: 19029636
[TBL] [Abstract][Full Text] [Related]
25. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.
Erdoğdu D; Gelincik A; Canbaz B; Colakoğlu B; Büyüköztürk S; Tanakol R
Int Arch Allergy Immunol; 2013; 160(2):215-7. PubMed ID: 23018845
[TBL] [Abstract][Full Text] [Related]
26. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Cappellini MD; Carubbi F; Di Rocco M; Giona F; Giuffrida G
Blood Cells Mol Dis; 2023 Jan; 98():102705. PubMed ID: 36327675
[TBL] [Abstract][Full Text] [Related]
27. Gaucher disease: a diagnostic challenge for internists.
Cassinerio E; Graziadei G; Poggiali E
Eur J Intern Med; 2014 Feb; 25(2):117-24. PubMed ID: 24090739
[TBL] [Abstract][Full Text] [Related]
28. Gaucher disease: a model disorder for biomarker discovery.
Boot RG; van Breemen MJ; Wegdam W; Sprenger RR; de Jong S; Speijer D; Hollak CE; van Dussen L; Hoefsloot HC; Smilde AK; de Koster CG; Vissers JP; Aerts JM
Expert Rev Proteomics; 2009 Aug; 6(4):411-9. PubMed ID: 19681676
[TBL] [Abstract][Full Text] [Related]
29. Use of Identical INN "Imiglucerase" for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database.
Tsang SF; Pandya S; Barakov K; Keutzer J; Lewis G; Ross L; Freisens S
Drug Saf; 2022 Feb; 45(2):127-136. PubMed ID: 35020177
[TBL] [Abstract][Full Text] [Related]
30. Gaucher disease: pediatric concerns.
Elstein D; Abrahamov A; Dweck A; Hadas-Halpern I; Zimran A
Paediatr Drugs; 2002; 4(7):417-26. PubMed ID: 12083970
[TBL] [Abstract][Full Text] [Related]
31. Giant lymphadenopathy infiltrated by gaucher cells mimicking lymphoma.
Yağci B; Salor O; Yalçin B; Gürakan F; Güçer S; Büyükpamukçu M
Pediatr Blood Cancer; 2009 Jul; 52(7):870-1. PubMed ID: 19213078
[TBL] [Abstract][Full Text] [Related]
32. National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model.
Kesselman I; Elstein D; Israeli A; Chertkoff R; Zimran A
Blood Cells Mol Dis; 2006; 37(1):46-9. PubMed ID: 16824774
[TBL] [Abstract][Full Text] [Related]
33. Gaucher disease, enzyme replacement therapy, and the Patient Assistance Program.
Goldwater RS
J Intraven Nurs; 1996; 19(2):83-8. PubMed ID: 8852168
[TBL] [Abstract][Full Text] [Related]
34. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.
Weinreb N; Barranger J; Packman S; Prakash-Cheng A; Rosenbloom B; Sims K; Angell J; Skrinar A; Pastores GM
Clin Genet; 2007 Jun; 71(6):576-88. PubMed ID: 17539908
[TBL] [Abstract][Full Text] [Related]
35. Disease state awareness in Gaucher disease: a Q&A expert roundtable discussion.
Mistry PK; Weinthal JA; Weinreb NJ
Clin Adv Hematol Oncol; 2012 Jun; 10(6 Suppl 8):1-16. PubMed ID: 22895100
[TBL] [Abstract][Full Text] [Related]
36. [Presenting signs and symptoms in Gaucher disease].
Erdös M; Tóth J; Maródi L
Orv Hetil; 2002 Oct; 143(41):2327-35. PubMed ID: 12434734
[TBL] [Abstract][Full Text] [Related]
37. Orthopaedic manifestations of Gaucher disease.
Lutsky KF; Tejwani NC
Bull NYU Hosp Jt Dis; 2007; 65(1):37-42. PubMed ID: 17539760
[TBL] [Abstract][Full Text] [Related]
38. Secretion of human glucocerebrosidase from stable transformed insect cells using native signal sequences.
Sinclair G; Pfeifer TA; Grigliatti TA; Choy FY
Biochem Cell Biol; 2006 Apr; 84(2):148-56. PubMed ID: 16609695
[TBL] [Abstract][Full Text] [Related]
39. Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
Pleat R; Cox TM; Burrow TA; Giraldo P; Goker-Alpan O; Rosenbloom BE; Croal LR; Underhill LH; Gaemers SJ; Peterschmitt MJ
Mol Genet Metab Rep; 2016 Dec; 9():25-28. PubMed ID: 27722092
[TBL] [Abstract][Full Text] [Related]
40. [Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher Disease].
Drelichman G; Linares A; Villalobos J; Cabello JF; Kerstenetzky M; Kohan RM; Martins AM
Medicina (B Aires); 2012; 72(4):273-82. PubMed ID: 22892077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
